Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein SNAI1 (Snail) mRNA is the transcript encoding a critical transcription factor that serves as a master regulator of the epithelial-mesenchymal transition (EMT) [1][2]. In this biological process, epithelial cells lose their characteristic polarity and cell-cell adhesion, gaining migratory and invasive properties typical of mesenchymal cells [2][3]. While essential for normal embryonic development and wound healing, the aberrant activation of Snail mRNA in adult tissues is a hallmark of cancer progression, where it promotes metastasis and confers resistance to chemotherapy and radiotherapy [4][5]. Snail primarily exerts its effects by binding to E-box elements in the promoter of the E-cadherin gene (CDH1), leading to its transcriptional repression and the subsequent breakdown of the epithelial architecture [3][6]. Given its central role in aggressive tumor phenotypes and poor clinical prognosis, Snail mRNA is a high-priority target for novel therapeutic strategies [7]. Current drug development efforts focus on using small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) to degrade the mRNA transcript, effectively silencing Snail expression to inhibit tumor spread and restore sensitivity to standard treatments [8][9]. Sources: [1] UniProt (P15172) [2] Peinado, H., et al. (2007). Nature Reviews Cancer, 7(6), 415-428. [3] Batlle, E., et al. (2000). Nature Cell Biology, 2(2), 84-89. [4] Wu, Y., & Zhou, B. P. (2010). Cancer Letters, 297(1), 18-36. [5] Kaufhold, S., & Bonavida, B. (2014). Journal of Experimental & Clinical Cancer Research, 33(1), 62. [6] Cano, A., et al. (2000). Nature Cell Biology, 2(2), 76-83. [7] Wang, Y., et al. (2013). Journal of Cancer Molecules, 7(1), 11-19. [8] Villarejo, A., et al. (2014). Cancer Research, 74(15), 4080-4091. [9] Zhou, J., et al. (2019). Molecular Therapy, 27(4), 780-791.
RNA interference (RNAi) or antisense-mediated degradation of mRNA to prevent the translation of the SNAI1 protein, thereby inhibiting the epithelial-mesenchymal transition.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein SNAI1 (SNAI1) mRNA (SNAI1).